Good morning, ladies and gentlemen. Thanks for joining our call today, and welcome to our quarterly analyst conference. My name is Sebastian, and I'm the head of investor relations, and with me as usual, our President and CEO, Dr. Markus Weber, and CFO, Justus Wehmer. I'd like to hand over to these gentlemen now to give you a quick introduction to the financials in form of some prepared remarks, and afterwards, we look forward to the Q&A session with you. Thank you so much, Sebastian, and also, Good Morning from my side, ladies and gentlemen. A warm welcome to the three months 2021, 2022 analyst conference of Carl Zeiss Meditec AG. What is today on the agenda? I will start first to give you an overview over the results, and then as usual, our CFO, Justus Wehmer, will give you more details on the financials in the next section of the presentations. Afterwards, I would like to share some highlights, and finally, I would like to talk about our outlooks. Let's come to the first slide giving our key performance. Overall, A very solid revenue growth and strong order intake in the first three months of 2021, 2022. Q1 was a very successful start into the new fiscal year and entirely according to our expectations. Revenues reached EUR 410 million, a strong increase compared to prior year, supported by small positive currency effects. Constant currency revenue at EUR 408 million, eleven percent growth, especially due to a positive development in Asia, also an increase in EMEA and Americas. Good news here is that both SBU's significantly contributed to that and had a significant increase. More information in more detail will be presented by Justus Wehmer. Our supply situation is still tense and requires high attention of the entire organization. We have taken various measures to reduce our limited negative effects as much as possible. The EBIT margin decreased to 18.1% versus 19.9% in prior year, due to also reported and expected increase in OPEX. Please keep in mind that last year's Q1 was really outstanding, also due to an extraordinary low level of OPEX due to the COVID situation, especially here, also travel restrictions. Our net income reached EUR 38 million, which corresponds to earnings per share of 0.42 EUR. Direct comparison to last year was 0.52 EUR. This includes, as already reported, some negative currency effects on our hedging contracts. With this, I would like just to summarize that overall the development is quite positive despite the corona situation. Now my colleague, Justus, will discuss the figures in more detail now and will give you more background. Thank you, Markus. Good morning, and also welcome here from my side. I'm now going to give you a more detailed overview of our financials, as Markus said, starting with the performance of our strategic business unit, OPT. Revenue came in for OPT with EUR 311 million. Compared to prior year, this is a reported increase of 9.7% and at constant currency, 9.1%. Both our devices and consumables enjoyed solid growth, especially in our refractive business; we saw again a great development. As expected, EBIT margin decreased compared to last year primarily due to increased expenses in sales and marketing activities. Trade shows take place again physically. More international traveling is possible again, and the cost per traveled mile is also trending upwards. On top, we also saw an increase in R&D expenses to support our strategic innovation initiatives, like for example, our digitalization program. MCS delivered a positive performance with revenue of EUR 99 million versus previous year's EUR 85 million. This represents an increase of around 16.1% and at constant currency, 15.2%, which is a good growth given the COVID-19 situation. We clearly benefit from the across-the-board rejuvenated portfolio in a market that has returned to invest. Our EBIT margin is still very strong and even improved versus last year, despite increased expenses, especially in sales and marketing. We do feel pressure on our COGS from various supply chain issues, but a favorable product mix helped to offset this effect. Let us next look at the regional development, which varies quite a bit across the globe due to differing COVID-19 developments. The Americas reported revenues of EUR 115 million, an increase of 12.3% with quite a bit of currency tailwind from the U.S. dollar. At constant currency, the increase would have been 8.4%. The U.S. showed with 14% and constant currency 10% growth, A really solid performance. But also Latin America with an increase of roughly 12%, was good. However, compared with the rather weak Q1 in last year, EMEA invoiced EUR 140 million, which is an overall increase as reported of 5% respectively 5.9% at constant currency. The developments per country vary quite significantly depending on the country's specific lockdown policies to manage the Omicron waves in fall and winter. We see double-digit growth in some countries, for example, Spain, but also only minor growth or even negative growth in countries like France or Germany. In Asia Pacific, we yielded revenues of EUR 182 million, +14.8% as reported and at constant currency, slightly higher at 15.1%. Again, outstanding performance from China, including Hong Kong. In other countries, just like in Europe, it's a widespread of powerful growth where the pandemic was hitting hardest a year ago, and a little or none growth where countries today struggle again with Omicron outbursts. Let's have a look at the P&L line. The gross margin is rather stable at roughly 57% compared to previous year, supported by some positive foreign exchange effects, mainly from US dollar, as I just explained on the previous slide. OPEX increased mainly due to the COVID development and strategic investments. Our sales and marketing expenses increased noticeably while advertising and trade show activities increased across the globe. We had the ESCRS in October in Amsterdam and the AAO in New Orleans in November. We had also increases in variable expenses like freight and personnel expenses supporting our product launches. R&D increased due to continuous investment in strategic development projects, mainly in the field of digitalization. EBIT came in at EUR 74 million, slightly above prior year's level of EUR 73 million. However, let us keep in mind last year's one-time effect, in other results of, two point four million euro due to the sale of our office building in Jena. This transaction, as we explained, is related to the construction of a new, Carl Zeiss building here in Jena. With an EBIT margin of 18.1% in our Q1, we are overall pretty pleased and see it as a confirmation for our guidance of 19%-21% EBIT margin for the fiscal year 2021-2022. Quick look at the adjusted EBIT margin, which reached 18.6%. There are rather small effects related to purchase price allocation, related depreciation in both periods, and we adjusted the one-time effect related to the asset sale in prior years. Finally, a short look at the cash flow statement. Operating cash flow was negative with EUR 15 million. This is significantly below previous year's EUR 41 million, in particular, due to the working capital development and tax payments in Q1 to some extent, of course, related to prior year's positive results. Our working capital saw further increase in accounts receivables due to the strong sales development in the end of the quarter and growing inventories, also to support our supply chain, and also due to repayments of payables. Cash flow from investing activities is mainly payments for property, plant, and equipment, especially the China production and some other locations in which our IOL production is being expanded. You will hear more about the China production facility later from Marcus. Cash flow from financing activities mainly influenced by changes in receivables and payables on our treasury accounts, and net liquidity is now at a level of above EUR 900 million. Thanks for your attention. With that, I hand it back to Marcus. Thank you so much, Justus. Now I would like to share some highlights with you. Justus already mentioned some of them, actually now even more in detail. Let's get started maybe first with the VISUMAX 800, which enables fast robotic connected laser vision correction. At the end of last fiscal year, we already introduced you to significant innovations. In our analyst conference in December, we actually focused on the QUATERA, so the phaco machine, the new phaco machine, and the cataract workflow. We continue to be very excited about this business opportunity. This is really running very nicely and very smoothly. We are seeing the first installations of QUATERA and continue to receive highly encouraging feedback as we move forward to seek the necessary regulatory approvals in all markets. In December, we have not talked so much in depth about our second-generation femtosecond laser device, the VISUMAX 800. Please let me provide you some context around it today and some more details. The device will further solidify our market and especially also our technology leadership in refractive surgery. The new VISUMAX 800 has exciting new features enabling more speed and automation with a better surgical workflow. Therefore, we refer to it as a fast robotic and connected laser vision correction system. The biggest advantage of it is definitely the speed and the high degree of automation. The device can create a lenticule in less than 10 seconds, and when you compare that to our last system, this is acceleration of a factor of 4, so that means 40 seconds with the previous generation. The resulting shorter section time can reduce significantly stress for patients and further improve patient safety and the risk of rare complications in case of a section loss. Moreover, as a second argument, the VISUMAX 800 connects seamlessly with our other diagnostic products and solutions from ZEISS, enabling easier treatment and planning and handling of the data. This is exactly our digital workflow and the next step in workflow solutions. Lastly, the device is smaller and more compact than its predecessor, which can be an advantage at certain customer sites. We have been able now to generate first installations in Europe, and the order entry looks quite strong at this early stage. There's a very, very well-filled order book. Let's come now to the next highlight of today. This is the first IOL deliveries from the new Guangzhou consumables manufacturing plant. This is something which goes directly in our manufacturing strategy. We want actually now today announce a significant expansion of our global footprint. In September 2021, the first batch of monofocal intraocular lenses was shipped from our new factory in Guangzhou in South China. We have been working on this new consumable plant for many years to further expand and diversify our global manufacturing strategy. In IOL production, specifically, we are targeting on the one hand, significant reduction in our cost of goods sold. On the other hand, it also represents a substantial capacity expansion for our IOL business, reflecting our strong ambitions for future growth plans. Operating the site also enables us to claim local manufacturer status in China, which is these days crucial and key, which can be helpful to mitigate the impact of new regulations in the Chinese market over time. It also sets us up well to mitigate the impact of potential future restrictions on world trade if they were to happen. Last but not least, it also improves the efficiency of our supply chain through additional local sourcing options and reducing transport costs and CO₂ emissions if the consumables are delivered into the markets of Asia Pacific. Quite positive and also in terms of sustainability. Regarding the infrastructure, We are able to benefit from substantial on-site synergies with the ZEISS Vision business that operates part of the facility. We strongly believe that the Guangzhou site will be a significant competitive advantage over time for our consumable strategy. A lot of great highlights. Now, coming to the outlook as the last topic for today. Especially also for the fiscal year, but also for the midterm guidance. We believe although our industry is still strongly impacted by the COVID-19 pandemic, we believe that it will continue to benefit from highly favorable long-term growth trends. What are these growth trends? The first one, as you can all imagine, is the aging of the population or aging of society. Second, growing wealth in large parts of the world. Third, rising access to healthcare in the rapidly developing economies. Lastly, fourth, increasing information access. These trends lead to a growing number of patients and thus even a higher load to the healthcare systems. Lastly, digital solutions. Telemedicine, remote, augmented, or artificial intelligence-driven features are becoming more and more relevant for ophthalmology. This is something we want to address and where we want to be the market shaper. The outlook for fiscal year 2021-2022 is quite positive. We aim to outperform our markets. Not only ZEISS, but the entire industry is impacted by the tense situation of the global supply chain. We cannot rule out an additional impact on market growth from it, but we have a very strong team in place and very good processes actually to address it. As we have pointed out, we have finished last year with a substantial order backlog, and it is very hard to say how long the situation will last. We estimate our EBIT margin for fiscal year 2021-2022 to be between 19%-21%, which would be down slightly from the record levels of the last fiscal year. As we have been seeing already in the current quarters, we expect more normal levels of operating expenses, particularly in sales and marketing. This applies even more so in the context of our product launches. Midterm, we continue to have significant investment needs as we want to further broaden our global presence and want to continue to drive our innovation strategy with a higher level of R&D investment. However, on the other hand, we consider the high level of recurring business is mostly sustainable. Profitability will clearly benefit from this trend. As a result of higher costs, but more also a higher level of recurring business, we are very confident that we can achieve EBIT margin sustainably above 20%. With that, we have come to the end of our prepared remarks on the financials. I hope you enjoyed it. Let me pass it back to the moderator, to Sebastian, to move into the Q&A session. Thank you so much. We can go to the Q&A session moderator, please. Ladies and gentlemen, if you have a question for our speakers, please dial zero and one on your telephone keypad now to enter the queue. Once your name has been announced, you can ask a question. If you find your question is answered before it's your turn to speak, you can dial zero and two to cancel your question. If you're using speaker equipment today, please lift the handset before making your selection. One moment, please, for the first question. The first question is from Axel in Bank of America. Your line's now open. Perfect. Thank you very much for taking my questions. I'll keep it to two, please. I guess the first one on the order book was considerably larger than at least we had expected. I'm fascinated to get any color you might be able to give on what the main drivers of that were, you know, where you were really seeing the strongest demand, and how we should think about how that flows through into revenues through the year. That's the first question, please. And then the second question, I'm just curious on pricing. 'cause obviously supply chain's been pretty messy across the board. We've had some companies that we never expected to be able to take pricing, putting through little bits of price increases to either distributors or their customers to help offset. Is that something that you guys have been doing or thinking about? Are there some categories where it's worth it or is it just a case that you keep pricing flat and take the supply chain costs in the meantime? Thanks. thanks, Anchal Verma. Here's Justus Wehmer. Maybe I'll start with the question about the order book and then Maximilian Foerst can make some comments on the pricing. color on the order book. Let's maybe rewind quickly to compare with last year. our growth in the order book was mainly driven by the consumables, simply representing the fact that after the lockdowns many of our customers started first to push their basically their business with laser vision correction and the IOL implantations providing good cash flow to their clinics and offices. We clearly saw a year ago still some reluctance for investments in CapEx. That has clearly changed, and you may remember that we already saw in our Q4 a good upswing in order entry, especially also for our MCS business. That trend now actually has further continued. That means the order book right now actually evenly benefits from both the good demand for the consumables and an appetite to invest also in our higher ASP devices, like Marcus just explained, the VISUMAX or the KINEVO from MCS. So I'd say that's pretty much the flavor that I can share with you on the order book. On the pricing, maybe just a couple of comments. Yes, of course, we feel the dent in our input costs from the current, let's say increased pricing for some of the components that we utilize. Overall, I'd say, we have a portfolio which probably at least in some markets, certainly permits us to also compensate for that price increase in our list prices, that we basically, give to our customers. From that, we hope that over the course of the year, we can somehow compensate for these impacts. We will probably see some volatility on our gross margin over the course of the year and just hope with the normalization of the supply chain, that this effect in the end will kind of fade out. Thank you for taking my questions. Great. The next question is from Maximilian Foerst. Your line is now open. Great. Good morning, and thank you for taking my questions. My first one is on the order book as well. Your order intake is still quite impressive, but it seems delivery times might get longer and longer. My question is there risk that some of these orders might evaporate if deliveries take simply too long? Can you share some insights whether you have already seen cancellations here? My second question is on your supply chain. I was surprised that you have not provided more details on this in the slide set. Could you elaborate, please, about the current situation, how much of the margin contraction is explained by this? Further, how do you expect the situation to evolve into the year? Thank you. Okay. Marcus, let me start with the first question on the order book and the risk of losses due to the delivery times. First statement, for the time being, it is not an issue, cancellations or anything of that nature that we observe, simply for two reasons. On the one hand side, W e are not the only ones right now who basically have to cope with longer lead times. Secondly, F or a good portion of our portfolio there is not too much alternative that you can buy if you think about the lasers for refraction, for example, or for the microsurgical products. However, that doesn't mean that we are not worrying about that, and therefore we actively communicate and are very transparent to our customers about the tensions that we are going through. From that perspective, I'd say overall, we feel confident that actually this order book will eventually be totally converted into revenues. On the supply chain, I'd say, in so far, number one, we have not had any interruptions in our operations, neither for consumables nor for devices. Th at's first of all an important message here to convey. Why is that? Our purchasing and supply chain organization, which we have significantly beefed up, so to speak, is working diligently to basically make sure that the inflow of components is not interrupted. Obviously we cannot predict what's happening next, but we somehow at least are confident that we continue to be able to maintain our operations in flow. On the margin impact, again, as I said before, it's a volatile situation. There is depending on our product lines, there are probably products that have anywhere between 50 and 100 basis points impact on margins. In a monthly average, what is even more important is the total mix of what we have invoiced to then basically ultimately decide whether we see these impacts shine through in our margin or not. If you now look at our Q1 margin for the group, that is actually the highest ever we had in the Q1, although we have the issues in the supply chain. As I said, it's too many factors that are basically playing into that game. I hope it helps you to understand a bit better, but I think the message that I wanna bring across is, if our supply chain situations were of a nature that is critical or even interrupting, then we certainly would have provided more detail in our presentation. We, I think so far, have been managing quite well. Thank you. May I follow up here? In your current guidance, do you assume an improvement in the supply chain situation? Until which quarter would it need to improve so that you still can make your profitability, at least the lower end? That would be my follow-up question. I mean, our current guidance is the guidance that we gave last year, first of all. I think the assumptions were that we would see during this entire fiscal year still some volatility as a cause of Corona, and that volatility has different aspects. It is on the one hand side, as we can see right now that this Omicron wave is still in some locations in the world causing interruptions. We see in the supply chains basically the tail end effects of the first, second, third and fourth wave of Corona. I think that picture remains unchanged. We will have to manage through a year which will provide different challenges. That is exactly why we gave the range of 19%-21%. Therefore, Marcus, I'd say no different view today. This volatility is built in that margin, but I wanna repeat what I said. Given these circumstances, we are actually quite satisfied with the margin that we could deliver now after Q1. Great. Thank you. The next question is from Oliver Reinberg, Kepler Cheuvreux. Your line is now open. Oh, G ood morning. Three questions anyway, the first would be for Marcus. Marcus, you already indicated in December that we should not expect any kind of larger deviation in terms of corporate strategy. After you've now been in office for a few months, can you just share any kind of thoughts like where would you further sharpen the focus in terms of strategic priorities, leaving supply chain issues aside for a second? The second question would be on China. Can you just comment in terms of what do you see in terms of VISUMAX equipment orders at the moment? Secondly, can you just share your thoughts in terms of when China so far still follows this kind of zero-COVID policy, and obviously the country has less natural immunization, less effective vaccines. If at some stage they would deviate from this policy and opening up this kind of system, what would be the impact in your view for refractive and cataract demand? The third question, can you just provide any kind of color in terms of the questions that have been raised, by the FDA on the QUATERA phaco machine? Thanks so much. Thank you so much, Oliver. I'm happy to take the first question. Se cond and third will be answered by Justus Wehmer. Oliver, as you said, maybe just to keep in mind, I'm already now 20 years with the Zeiss in general, and in very close interaction with Meditec roughly since 12 years. That means, actually, I was always in a way involved in the activities there. Especially the strategy which has been completely built up last year. The corporate strategy is, from my point of view, a very strong one, a very good one, a long-lasting one, which Actually significantly pushes the growth potential further on. For me, the strategy is great. For sure there will be always some updates over time, but this is for me just evolving effect and a kind of continuous improvement. For me now, and especially also in discussion with the teams after six weeks now being in charge as a CEO, I see especially strategy implementation and operational excellence. Oliver, you mentioned that in terms of the supply chain. We want to make sure that we even strengthen our operational excellence. That means strong focus on the supply chain together with our suppliers on the one hand. On the other hand, but also, to ensure that we get our market entries and market penetrations for the new products to make sure that we can do that so that we are building up the entire operational excellence. This is starting the sales and marketing. This is also the reason of their higher investments there. Hence, this regulatory to make sure that we get the clinical trials in time and to ensure that we have a proper market start. This is the topic here. Overall, team is responding super well. T here's a super high energy and a very positive aspect in that regard, and as Justus already mentioned, supply chain and the pandemic and the effect of the pandemic is very dynamic. The team is tense. There's a lot of tension inside, but the team is very encouraged actually to take this challenge. Ov erall, just in a nutshell, continuing the strategy, corporate strategy that's for sure, especially with a strong focus also in digital and in the workflow solutions, and then operational excellence combined with strategy implementation. Okay. I take over on the China questions. Oliver, you were asking about the order book for VisuMax. The order book is strong. We still enjoy a good solid demand from China for the VisuMax products. As we have shared with you, some of our key customers in China have publicly announced that they further wanna expand and grow their business, and we clearly benefit from that. With regard to your question on the China zero COVID policy, I'm not sure whether I understood 100%, but I may try to answer what I thought you are asking for, and if not, then just come back. We monitor very precisely the number of clinics in China that is open or closed. So far from the local lockdowns in China, we have actually not seen any significant impact on the total number of clinics being open. Those lockdowns that happened as we all have seen were mostly limited to durations of two weeks or three weeks. With that, even though it's a bit of a moving target, but the overall number of clinics is pretty stable on a high level open and active. That's why we also see that reflected in solid demand for our consumables. On the third question, which was on the FDA approval for QUATERA, I mean, we are not disclosing here any technology details, but as t here were some supplementary questions that the FDA had asked us to provide and to answer. That process is ongoing. From our best knowledge, we would right now think that in early summer of this year, we should then finally have concluded the registration process and can fully start with the commercialization. We move on to the next question. It is from Alexander Galitsa at H&A. Your line is now open. Yes. Hello. Thank you very much for taking the question. I'd like to ask on the VISUMAX, how do you see the dynamics of customers sort of expanding and ordering new machines versus a sort of a replacement demand here? If you could give any comments around that. Alexander Galitsa, I can do that. I mean, as you have seen from Maximilian Foerst's report, it has one different feature, which is basically that it has a significant amount of footprint this device. That certainly opens up a couple of opportunities in accounts which simply you know were located in high streets clinics where the footprint is let's say an important factor, so to speak, whether one can expand its clinic and invest in a laser or not. I'd say there are certainly some opportunities. Overall, I'd say I see us growing with our satisfied customers. I just mentioned the importance of us cooperating with some of the big global players, EuroEyes being one, AIER Group being another one. They are very happy and satisfied with our current laser, but they certainly wanna also continue to work with us, and they are actually pretty much driven by efficiency and productivity in their clinics because they are specializing on this. Therefore, we feel that in this market, not only will we benefit from replacing systems that come to end of life, but we also hit basically a demand of the market of higher productivity. From that perspective, we hopefully can enjoy continued growth with these chains. Thank you. Maybe just one quick follow-up on that. With this, sort of additional value add to the customer, is it fair to assume that you also reap benefits for your company in terms of pricing? I see potential for pricing. I see potential for higher consumption of treatment packs. I think maybe to add on that, as you know, it's a razor blade business end, and that means for us the business model is on the one hand, the consumables, the treatment packs, combined with the device systems. As Justus said, actually these markets addressing totally different demands from customers. On the one hand, really highly efficient, that means a clear workflow solution, very digital, but we can offer to the market so that the industrialization process and customer process is even further improved with higher patient comfort. On the other hand, as Justus said, it's ergonomics. Ergonomics is something that this system offers, not only in footprint, but also in the way how to handle the patient with the system. That creates a lot of opportunities for us. That means we will also go in a value-based pricing to make sure that actually the system is represented as a total system in the market that's relevant and the right price there. That makes sense. One more question on the Chinese IOLs production plant. How to think about it in terms of sort of related pre-production costs? Is it already mostly in the P&L, or should we expect any dilution stemming from there, at least while the volumes are ramping up? I'd say you can expect that we will maintain our positive in a market where we anticipate more price pressure in the future. With that, obviously, we not only want to be able to participate as a contender with the local content which gives us volume but then also defend our margin in comparison to other competitors that potentially will obviously try to enter with pricing a differentiator. Thank you. Just in terms of, kind of mechanics, this new facility in China that's already sort of being depreciated, so you have related D&A in the P&L? Yes, we have. Understood. Thank you. The next question is from Daniel Wendorff of ODDO BHF. Your line is now open. Good morning, and thanks for taking my questions. Three, if I may. One follow-up on the order book questions. Over what period of time is your order book normally transferring into sales? That would be my first question. Second question would be, how big is your SMILE business suite overall, meanwhile, in the U.S., and how is that growing or has this been growing over the last few quarters? Any more color you can provide here, I would appreciate. Last question, a follow-up on the QUATERA question for the U.S. How does your launch plan overall look like overall for the cataract suite in the U.S.? Also thinking about the IanTECH Phaco Sling technology here. Any more color here would be appreciated. Thank you. Thank you. I start with the order book question. T he transfer into sales obviously depends on the product, the specifics, and that varies, you know, from weeks to months or quarters, I should say. Therefore, it is certainly right now prolonged simply due to the, as we already said, the lead time difficulties that we see right now. Your question, until when will this be completely transferred into sales? I would hope that the majority of our order book today will be converted within this fiscal year. Ideally, again, hoping that the supply chain situation will improve over the course of the summer, that is then maybe completely consumed until we have reached the fiscal year. Again, that's still speculative, not knowing what's really going to happen with the global supply chain. SMILE business in the U.S., overall still positive. We continue to increase our consumable business in the U.S. From all we know, all the, let's say, public data on the market, B y now we seem to have reached roughly a market share in the U.S. with SMILE of 10% of all the procedures for laser vision correction, which is quite a significant improvement. If we look back only a few years then we probably would have been rated much higher than maybe 2 or 3%. we are very pleased with that development and we could grow our installed base over the last year and most likely installed base of lasers and most likely are going to continue to do so during this year. On the QUATERA you were asking about the launch plan. The launch plan we always guide it to everybody that do not expect from the U.S. launch this year any significant impact on top or bottom line in our P&L. That has not even so much to do with the delay in the FDA approval. Even if we had it already today, it is clear that we enter this market, which is the home turf of some of our key competitors, and we basically have to have there probably somewhat patient until it is we are growing a visible position here. However, in a nutshell, the launch plan is pretty much that we obviously have huge installed base of biometry and ophthalmic microscopes. These customers know us. These customers, we can demonstrate the integration of the workflow of the QUATERA with their existing ZEISS devices. Obviously, we can package our deal with the IOL that we are going to launch in the U.S. also this year. Having said that is certainly the key focus of our launch plan for this year. With that, we hope that we can build basically the first lighthouse installations from which we then can develop the market. On the IanTECH, maybe only a word, we are still in the development of that product. It is not yet registered for the U.S. market, so we have to have a bit more patience, but we will add it to our solution portfolio as soon as we have basically completed the registration process. Thank you. Okay. Thank you. The next question is from Sezgi Oezener, HSBC. Your line is now open. Hi. Thanks for taking my questions. My questions first, I will have two, please. First about operational cash flows. In the first quarter, you shortly commented that it's due to ramp up of inventories and payables. Can you comment a little bit about the further outlook? To what extent do you expect a correction? My second question is, SG&A expense increased because of trade fairs, but we also know that we weren't quite out of the COVID restrictions yet. Do you think that the rise in SG&A expense has already happened to its full extent, or do you expect further rise? Thank you for your question. On the operational cash flow, again, it's ultimately a function of the supply chain situation. If we see a need for buffering and therefore increasing our working capital in order to, on the other hand, secure our operations being at all times basically producing, then we will certainly do that. However, I'm confident that overall the outlook should be positive for our operational cash flow driven by our typically stronger Q2 and Q3 operational performance. I would think that there is some, how should I say, upside for the cash flow development. On the SG&A, basically, our numbers for the first quarter confirm exactly what was our expectation, in terms of the travel expenses and the activities in marketing. I mentioned two major global shows, the ESCRS in Europe and the AAO in the U.S. That is basically two of the three top shows each year in ophthalmology have taken place, and they were, basically almost as normal as pre-corona, and therefore, the expenses have hit us. It is, as I say, pretty much what we were thinking it would happen. Your expectation or your question, will we even see a higher increase of sales and marketing expenses as a ratio of revenue? I would hope it would stabilize at that level that we have seen right now. Okay, thanks very much. Welcome. The next question is from Samuel Andrew England. The Berenberg line is now open. Thank you. I have two questions. First one is on microsurgery. The expected pressure through the Omicron wave did not materialize in most hospitals, and also, many countries are lifting all restrictions. Is it fair to assume that the dynamics in the microsurgery or the intake will even increase in the coming months? The second question is on the consumables business. Do you see currently customers building up their inventories more in advance than usual because they are afraid of shortages? Thanks. Sorry, I didn't understand your name. Can you repeat it? Samuel England, DZ Bank. Sam, MCS, I'd say overall our prospects for this year for MCS remain positive. As I mentioned in my presentation of the numbers, I think we clearly see that the total portfolio, and that's not only KINEVO, that's also EXTARO, TIVATO, they are all being well received in the market. They give us also a better position in the, let's say, mid-class or mid-price segment of the market, where previously we hadn't always been as competitive. I'd say that all together has on the one hand side explained the good order entry that we've seen in Q1, and that also provides some optimism for the next quarters for this business. Yes, I'd say overall, we are quite pleased with how the markets have returned and are quite positive for the outlook for MCS for this fiscal year. The consumables, you know, this building safety stocks at customers, I don't have evidence for it. T he pattern that we have seen are following pretty much the end patterns, where we typically, if we talk about the treatment packs, see a first peak in the Chinese New Year vacation period, and that has materialized quite nicely in our refractive treatment pack shipments in Q1. I do not really see or hear from our sales organization that there's a pattern that would indicate that there's some overstocking. No, I don't. I see it as a function of the increased installed base and its utilization, its increased global utilization. Thank you. Okay, thank you. We have a follow-up question. It is from Alexander Galitsa. Your line is now open again. Yes, thank you. Just briefly on R&D. You have stepped up R&D investments yet again now into digitalization, which is sort of curbing your short-term margin potential. Would you be able to maybe not speculate, but provide any color in terms of what kind of a lead time for your digitalization R&D expenses you would foresee, in the sense that until when we can think of sort of models and ways to monetize those? I'd say, as we said, we are building basically an ecosystem, and the first step is to basically invest in the connectivity of devices and then to bring things into the cloud. I certainly would think that this fiscal year, as we have guided, is going to continue to be a year in which we are working on the infrastructure and first applications that we can bring to market. I think a monetization we will probably not see before, you know, the next year or maybe even after that year. Let's also remind, our digitalization is not meant to completely change our business model. It is meant to implement another trigger point to drive our device, and with the device, the consumable business, simply by adding features that make it more attractive and more convenient to opt for a ZEISS solution. Let's not be misled thinking that we kind of shift our model to become a software provider or anything of that nature. That is not the intent, at least not for the next couple of years. What may evolve out of the ecosystem over time, you know, there are certainly potentially opportunities to also develop a bigger contribution from apps and data-related offerings as services. I'd say for your model, for the, let's say, midterm, I wouldn't guide you to expect such a development. Maybe just to add on this also from my side, as Justus said, the digital is actually the backbone for our solutions, for our workflow solutions. This means in this regard, especially when it comes to ophthalmology and refractive laser correction and cataract, this goes actually mainly in efficiency. So that means in gold standard processes, we can increase the digitalization efficiencies, and as Justus said, so this is actually strengthening our workflow and our position in the market for parameters which matter, besides the outcome, also very strongly for the customers. On the MCS side, it's a bit different because here we have a workplace solution. So that means it's cockpit in the OR. This is something where it comes more to outcomes. Where actually the connectivity helps to improve the outcome, especially. That means here we look more at that, actually, for instance, information sharing and information with artificial intelligence information enrichment. These are the two directions we are moving in, but not a principal change in the business models. Okay, it's all right. Thanks. Thank you very much. At the moment, we have no further questions. As a short reminder, if you would like to ask a question, please press 0 and 1 on your telephone keypad. We have no further questions, so I would like to hand back to Mr. Frericks for some closing remarks. Thank you. Thank you very much for participating in today's call. Please, as always, we'll be available for you in the days to come for further questions and wish you lots of success and happy weekend, and looking forward to our next conversations and meetings.